iSpecimen (ISPC) investor relations material

Company overview and business model

• Operates a technology-driven online marketplace connecting life science researchers with biospecimens and associated data from a global network of healthcare providers.

• Revenue is generated by procuring and distributing annotated biospecimens, with a flexible revenue-sharing model for suppliers.

• The platform supports both remnant and research-use-only specimens, including biofluids, tissues, and hematopoietic stem and immune cells.

• The supply network spans 55 organizations across 14 countries, with customers in biopharma, diagnostics, and government/academic sectors.

• The business model is transactional, not recurring, and relies on project-based customer demand.

Financial performance and metrics

• Reported net losses of $10.5 million in 2025 and $2.3 million for the three months ended March 31, 2026.

• Accumulated deficit of $84.6 million as of March 31, 2026.

• Revenue for 2025 was $1.93 million, with $1.06 million for the three months ended March 31, 2026.

• Cash balance of $2.8 million as of March 31, 2026; working capital of $17,771.

• Revenue is highly concentrated, with one customer accounting for 54% of revenue in Q1 2026.

Use of proceeds and capital allocation

• Net proceeds of up to $3.72 million (assuming full subscription) will be used for placement agent fees, offering expenses, outstanding liabilities, potential acquisitions ($700,000), marketing and advertising (up to $1 million), and general corporate and working capital.

• Outstanding liabilities refer to accounts payable and accrued obligations without interest or stated maturities.

• Management has broad discretion over the allocation of proceeds.